Trubion, formerly known as Genecraft, was acquired in 2010 by Emergent BioSolutions. The company had been a biopharmaceutical product company structured around the discovery, development and commercialization of novel medicines that will help in treatment of those with inflammatory disease and cancer. Trubion had proprietary product candidates in pre-clinical testing for indications in oncology and autoimmune disease. Trubion is leveraging a proprietary single chain antibody platform to develop novel therapeutics. The company currently has multiple proprietary product candidates in pre-clinical testing. Trubion’s product candidates are members of a novel compound class called SMIPs™ (Small Modular ImmunoPharmaceuticals)
